Charles River Laboratoire France Crlf086650041

Recherche-développement en sciences physiques et naturelles

les Oncins 69210 Saint-Germain-Nuelles

Indice de confiance

Laissez un avis

Chiffre d'affaires 2019

57,9 M€

Président

Colin

Dunn

Effectif 2015

309

Ancienneté

55 ans

Indicateurs

À propos

Every Step of the Way
Our mission is to comprehensively provide researchers all they need to develop new therapeutics for patients as rapidly as possible.Source : Facebook

Every Step of the Way.
As a fully integrated partner, Charles River can support your research at any point along the drug discovery continuum.Source : Twitter

At Charles River, we are passionate about our role in improving the quality of people’s lives.Source : Instagram

Every Step of the Way.

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts.

As a fully integrated partner, Charles River can support your research at any point along the drug discovery continuum.Source : Youtube

Charles River provides products and services to help expedite the discovery, early-stage development and safe manufacture of novel drugs and therapeutics.Source : Site web

Toutes études et recherches et notamment la réalisation de tests pyrogènes pour l'industrie pharmaceutique , obtention, acquisition, développement, exploitation, vente, cession, rétrocession, sous quelque forme que ce soit, dans tous les pays du monde, de toutes dénominations commerciales, de marques, de modèles, de dessins, de procédés, de systèmes, de formules et de secrets de fabrication, d'inventions, de demandes de brevets, de brevets, d'améliorations et d'extensions, de tous autres droits de propriété industrielle ainsi que l'acquisition, l'exploitation et la concession de toutes licences des droits décrits ci-dessus .Source : BODACC

Le n° de TVA correspondant à l'activité de Charles River Laboratoire France Crlf est : FR29086650041. Le lieu de son exercice se situe dans la ville de Saint-Germain-Nuelles. Son exploitation a commencé au cours de l'année 1966. Charles River Laboratoire France Crlf a pour n° de SIREN : 086650041. L'effectif de cette structure en 2015 était de 309 employés. Le capital de cette entreprise était de 69969360 € en 2004. La société Charles River Laboratoire France Crlf a un indice de confiance de 95/100, cet indice se base sur plusieurs critères. Colin Dunn est Président de cette société. La société exerce dans le secteur de la recherche-développement en sciences physiques et naturelles, le code NAF associé est 7219Z. Cette affaire est présente sur divers réseaux sociaux, Facebook et Twitter. Vous pouvez trouver la page Facebook de cette société sous la dénomination de charlesriverlabs et sur Twitter sous la dénomination de criverlabs. Une structure relativement énergique sur le net, elle compte 7684 adhérents sur Twitter et 19318 likes du côté de Facebook.

Fiche d'identité

  1. Type Société par actions simplifiée (SAS)
  2. Sigle CRLF
  3. Date de création 01/01/1966
  4. Effectif 309 (2015)
  5. Capital social 69969360€ (2004) (Source RCS)
  6. Chiffre d'affaires 57,9 M€ (2019)
  7. TVA intercommunautaire FR29086650041
  8. Numéro de SIREN 086650041
  9. Code NAF Recherche-développement en autres sciences physiques et naturelles (7219Z)
  10. Statut SIRENE Active
  11. Statut RCS Immatriculée (11/10/2004)

Contacts

Site web

Site internet de Charles River Laboratoire France Crlf

Réseaux sociaux

Téléphone

Emails

{[{emailItem.email}]}

*******@****er.com

****@****er.com

Obtenez des millions de téléphones et emails nominatifs.

En savoir plus

Il s’agit de votre entreprise ?

Mettez en valeur votre activité en complétant les informations de cette page et invitez vos partenaires à vous évaluer pour construire votre e-réputation.

Revendiquez votre page gratuitement !

Conformité

PRO

Accéder aux certificats de conformité

Assurez-vous de respecter la loi en vérifiant la tenue des engagements d'obligations de vigilance, SAPIN II et RSE de vos fournisseurs.

En savoir plus

Conformité

Obligations de vigilance

Statut du dossier d'obligations de vigilance

Le dossier de la société {[{company.usedName}]} est complet.

La société {[{company.usedName}]} n'a pas encore déposé tous les documents requis.

Loi SAPIN II (encadrant la corruption)

Évaluation Sapin II

Score Loi Sapin II

Membres répertoriés comme
Personnes Exposées Politiquement (PEP)

Sanctions connues

SAPIN II non certifié

Loi sur le Devoir de Vigilance (encadrant la RSE)

Note obtenue

Détails de son évaluation

Répartition des scores globaux

RSE non certifié

Avis Charles River Laboratoire France Crlf (0)

Que pensez-vous de Charles River Laboratoire France Crlf ?

Actuellement aucun avis publié, soyez le premier !

Laisser un avis

Dirigeants Charles River Laboratoire France Crlf (8)

Âge moyen des dirigeants

48 ANS

Durée moyenne de mandat

2 ANs 5 MOIS

Parité

0%100%
  • Colin Dunn

    Président

    2019 - Présent

    En poste

    **********@****er.com PRO

    {[{ company.directors.identities[0].email }]}

  • Julien Datin

    Directeur général

    Présent

    En poste
  • Aidan Synnott

    Directeur général

    2018 - Présent

    En poste

    *************@****er.com PRO

    {[{ company.directors.identities[2].email }]}

  • Benjamin Ville

    Directeur général délégué

    Présent

    En poste
  • Pricewaterhousecoopers Audit

    Commissaire aux comptes titulaire

    2019 - Présent

    En poste
  • Yves Nicolas Yves

    Commissaire aux comptes suppléant

    2019 - Présent

    En poste
  • Laure Collet-Trela

    Directeur général délégué

    jusqu'en 2020

    Ancien
  • Héloïse Cavey

    Directeur général délégué

    2019 - 2021

    Ancien

Employé Charles River Laboratoire France Crlf (1)

  • Michaël V.

    Surgery Projects Manager - Veterinarian

    *******@****er.com PRO

  • Vous voulez voir tous les employés ?

    Obtenez dès maintenant les mails nominatifs des employés clés

Chiffre d'affaires, bilans Charles River Laboratoire France Crlf (5)

Durée de l'exercice comptable : 12 mois

Comptes saisis avec des incohérences selon l'INPI

Chiffre d'affaires

57,9 M€

Résultat net

3,6 M€

Capacité d'autofinancement

5,9 M€

Vous voulez le détail des comptes ?

Inscivez-vous et téléchargez le bilan et le compte de résultat des comptes sociaux déposés en 2019 par Charles River Laboratoire France Crlf

Télécharger les comptes

Chiffres clés

Chiffre d'affaires

57,9 M€

Résultat net

3,6 M€

Capacité d'autofinancement

5,9 M€

La trésorerie générée par l'exploitation est correcte au vu de son chiffre d'affaires, et permet d'investir, verser un dividende, etc.

Taille du bilan

129 M€

Fonds propres

89,8 M€

Le ratio fonds propres sur chiffre d'affaires présente une valeur très élevée.

Trésorerie nette

7,6 M€

La trésorerie nette de l'entreprise est très abondante (40,7% du fonds de roulement suffisent au besoin en fonds de roulement) et pourrait même être mieux optimisée.

Ratios financiers

Rendement des fonds propres

6,4 %

La rentabilité des fonds propres est positive sur cet exercice.

Equilibre financier

108,1 %

Autonomie financière

69,6 %

La structure financière de l'entreprise est très solide grâce à des fonds propres abondants.

Liquidité générale

2,2

Délai moyen clients

65 jours

Le délai moyen apparent de paiement par les clients était de 65 jours à la date de clôture, au-delà de ce qui est prévu par la loi, sans être abusif.

Délai moyen fournisseurs

59 jours

Les dettes vis-à-vis des fournisseurs se montent à 59 jours d'achats en moyenne, ce qui pourrait indiquer que l'entreprise acquitte ses factures conformément à la loi LME.

Score financier

PRO

Accédez au score financier

Vérifiez et anticipez le risque de défaillance de vos clients, fournisseurs et partenaires.

En savoir plus

Liens capitalistiques

PRO

Accédez aux liens capitalistiques

Découvrez la structure du groupe auquel appartient cette entreprise : tête de groupe, actionnaire majoritaire et filiales.

En savoir plus

Contentieux Charles River Laboratoire France Crlf (1)

PRO

Accédez aux contentieux

Vérifiez et anticipez le risque juridique lié à vos clients, fournisseurs et partenaires.

En savoir plus

Annonces légales (37)

  • Modification

    25 mars 2021

    CHARLES RIVER LABORATORIES FRANCE - C.R.L.F. a remanié son administration :
    VILLE Benjamin Marie nom d'usage : VILLE devient directeur général délégué. VILLE Benjamin Marie nom d'usage : VILLE devient pharmacien responsable. CAVEY Héloïse Marie Léocadie nom d'usage : CAVEY n'est plus directeur général délégué. CAVEY Héloïse Marie Léocadie nom d'usage : CAVEY n'est plus pharmacien responsable.

  • Modification

    15 nov. 2020

    CHARLES RIVER LABORATORIES FRANCE - C.R.L.F. a remanié son administration :
    DATIN Julien Mathieu nom d'usage : DATIN devient directeur général. SYNNOTT Aidan John nom d'usage : SYNNOTT n'est plus directeur général.

  • Immatriculation

    10 nov. 2020

    Autre achat, apport, attribution.

  • Immatriculation

    6 nov. 2020

    Autre achat, apport, attribution.

  • Dépôt des comptes

    27 sept. 2020

    L'entreprise a enregistré ses comptes annuels et rapports, clos au 31/12/2019, auprès du tribunal de commerce ou d'instance.

  • Modification

    17 janv. 2020

    CHARLES RIVER LABORATORIES FRANCE - C.R.L.F. a remanié son administration :
    COLLET Laure nom d'usage : COLLET-TRELA n'est plus directeur général délégué. CAVEY Héloïse Marie Léocadie nom d'usage : CAVEY devient directeur général délégué. COLLET Laure nom d'usage : COLLET-TRELA n'est plus pharmacien responsable. CAVEY Héloïse Marie Léocadie nom d'usage : CAVEY devient pharmacien responsable.

  • Dépôt des comptes

    22 août 2019

    L'entreprise a enregistré ses comptes annuels et rapports, clos au 31/12/2018, auprès du tribunal de commerce ou d'instance.

  • Dépôt des comptes

    8 août 2019

    L'entreprise a enregistré ses comptes annuels et rapports, clos au 31/12/2017, auprès du tribunal de commerce ou d'instance.

  • Modification

    5 juil. 2018

    CHARLES RIVER LABORATORIES FRANCE - C.R.L.F. a remanié son administration :
    SYNNOTT Aidan John nom d'usage : SYNNOTT devient directeur général. DURANO Jean-Marc nom d'usage : DURANO n'est plus directeur général.

  • Dépôt des comptes

    22 mars 2018

    L'entreprise a enregistré ses comptes annuels et rapports, clos au 31/12/2016, auprès du tribunal de commerce ou d'instance.

  • Vous voulez voir toutes les annonces légales ?

    Créez un compte pour accéder à l'ensemble des données sur cette entreprise.

Adresses Charles River Laboratoire France Crlf (2)

  • Siret : 08665004100022 (siège social)

    Actif

    les Oncins 69210 Saint-Germain-Nuelles

    Recherche-développement en autres sciences physiques et naturelles (7219Z)

    31 août 2004

    250 à 499

    Siret : 08665004100048

    Actif

    2109 route de Chatillon 01400 Romans

    Recherche-développement en autres sciences physiques et naturelles (7219Z)

    1 janv. 2005

    20 à 49

  • Siret : 08665004100071

    Fermé

    9 allée Moulin Berger 69130 Écully

    Recherche-développement en autres sciences physiques et naturelles (7219Z)

    1 juil. 2013

    24 mai 2014

    Siret : 08665004100030

    Fermé

    01400 Romans

    1 janv. 2005

    1 janv. 2005

  • Siret : 08665004100063

    Fermé

    chemin de Moiry (Domaine des Gouttes) 69210 Lentilly

    Recherche-développement en autres sciences physiques et naturelles (7219Z)

    1 janv. 2005

    1 févr. 2013

    Siret : 08665004100055

    Fermé

    10 avenue du Quebec (ZA Courtaboeuf 1 Bat Dah) 91140 Villebon-sur-Yvette

    31 déc. 2004

    31 déc. 2006

  • Siret : 08665004100014

    Fermé

    59 rue de la Paix 76410 Saint-Aubin-lès-Elbeuf

    1 janv. 1966

    31 août 2004

Trafic du site web

Accédez aux statistiques du site web

Évaluez l'empreinte digitale de cette entreprise et son évolution grâce aux statistiques sur son trafic mensuel, ses sources du trafic, le temps passé par les internautes, etc.

En savoir plus

Réseaux sociaux Charles River Laboratoire France Crlf (4)

Vidéos Charles River Laboratoire France Crlf (50)

  • Concept to Cure: The Foundation of Drug Development

    1 mai 2019

    How does a therapy go from being a patient’s dream to reality? The drug development process is long, tedious and complex. We’ve broken it down into four simple steps to help you understand how a drug goes from just an idea to the shelves of your pharmacy. #everystepoftheway https://bit.ly/2KIeDFd For additional languages: Dutch – https://youtu.be/t6F3jWeotg4 French EU – https://youtu.be/jeA_HabIavc French CA – https://youtu.be/Yy09cmNGTnA German – https://youtu.be/kRlpeMhU4Y8 Italian – https://youtu.be/G6n5879hKPU Mandarin – https://youtu.be/8jlLt8YyCI4 Japanese – https://youtu.be/kpyJIf4zx-k

  • Evie's Story

    28 févr. 2018

    Behind every patient stands thousands of scientists and researchers working together to develop life-saving drugs. Watch Evie’s Story. #EveryPatient http://bit.ly/2EYTuXz

  • Be the Difference

    16 mars 2018

    At Charles River, our purpose is clear and our passion is strong: Together We Create Healthier Lives. Our values: Care, Lead, Own and Collaborate should guide our decisions and actions, they are the standards we hold ourselves to each and every day.

  • Every Life - Mila's Story (Full)

    16 oct. 2019

    http://bit.ly/2BabGcv Drug development can take more than 10 years. Meet the Boston Children’s Hospital and Charles River team behind a tailormade therapy that was developed in a fraction of that time, for a single patient. Watch Mila’s story. #EveryLife Learn more: »Eureka: https://bit.ly/35t23Dw »C&EN: https://bit.ly/2MkKcaq »Vital Science Podcast: http://bit.ly/2oUCtXZ . . . At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guides us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. To learn more, please visit: » Our website, criver.com » Eureka, our scientific blog, eureka.criver.com » Sounds of Science, our monthly podcast, eureka.criver.com/podcast » Vital Science, our monthly podcast, criver.com/vitalsciencepodcast » Bonus! You can subscribe to Sounds of Science and Vital Science on Apple Podcasts, Spotify or wherever else you get your podcasts. » Facebook, facebook.com/charlesriverlabs » LinkedIn, linkedin.com/company/charles-river-laboratories » Twitter, twitter.com/criverlabs » Instagram, @criverlabs

  • Sonia & Eric's Journey

    21 juin 2018

    What would you do if you learned you’d inherited a fatal genetic mutation for Prion disease? Follow lawyer-turned-researcher Sonia Vallabh and her husband Eric Minikel on their race against time. #raceagainsttime #everydaycounts #CRLWorldCon

  • Zebrafish

    18 janv. 2018

    The video (shown below) shows zebrafish development from a single cell through about 22 hours post fertilization.

  • What aren’t you seeing?

    26 janv. 2018

    Cancer Researchers, reveal your compound’s immunoreactivity in real-time.

  • Microdialysis services at Charles River

    26 sept. 2018

    Our team discusses the methodology and benefits of using microdialysis. Want to learn more about our microdialysis services? http://bit.ly/2OOYnU5

  • What does horseshoe crab conservation mean to you?

    7 mars 2019

    See how our partnership with Rutgers University is providing horseshoe crabs a jump-start on life.

  • Brains On-Line

    20 nov. 2017

    A look at microdialysis and bioanalysis in CNS research.

  • The Crusade to Cure Jack

    3 oct. 2019

    https://bit.ly/2AE8DJh Jack O’Brien Burke was born to Jake Burke and Elizabeth O’Brien in 2005. At age two, while the couple was expecting the birth of their second son Luke, they received a devastating diagnosis: Jack had neurofibromatosis (NF). . . . At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guides us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. To learn more, please visit: » Our website, criver.com » Eureka, our scientific blog, eureka.criver.com » Sounds of Science, our monthly podcast, eureka.criver.com/podcast » Vital Science, our monthly podcast, criver.com/vitalsciencepodcast » Bonus! You can subscribe to Sounds of Science and Vital Science on Apple Podcasts, Spotify or wherever else you get your podcasts. » Facebook, facebook.com/charlesriverlabs » LinkedIn, linkedin.com/company/charles-river-laboratories » Twitter, twitter.com/criverlabs » Instagram, @criverlabs

  • The Race

    7 févr. 2019

    For Logan, a Charles River scientist, Huntington’s disease research is focused around a repeating CAG gene. For Jenne, a young mother of two, Huntington’s disease research is hope. When Jenne discovered she carries the HD gene and only has a few years before she starts presenting symptoms, her world was turned upside down. Now she’s waiting while scientists at Charles River and CHDI Foundation race to find an effective treatment.

  • Celsis Advance II ™ for Microbial Limits via Direct Inoculation Testing

    31 mai 2019

    The Celsis Advance II is a rapid microbial detection instrument that falls in seamlessly with your current test routines for both direct inoculation and membrane filtration testing methods. For samples that are non-filterable, opaque, pigmented, or viscous, Celsis® systems are an ideal test method to screen samples for contamination in as little as 18-24 hours. To learn more about Celsis® rapid microbial detection from Charles River, visit criver.com/celsis.

  • CRISPR in Oncology

    17 avr. 2018

    Eureka’s Live discussion at AACR 2018

  • The Future of Antibody Discovery

    20 mars 2019

    High-throughput monoclonal antibody library screening has never been faster. Glimpse the future: www.criver.com/antibody

  • Charles River Featured on De Barometer (RLT-Z)

    19 juin 2019

    Originally aired in June 2019 on De Barometer (RLT-Z). Our discovery-focused site in Leiden uses a combination of functional genomics technologies coupled with screening in human (primary) cells to identify and validate critical proteins in disease pathways. Learn more: http://bit.ly/2ZBVlYa.

  • Celsis Advance II™ for Bioburden via Membrane Filtration Testing

    31 mai 2019

    This video demonstrates the simplicity of using the Celsis Advance II™ in conjunction bioburden testing via membrane filtration. When samples are filterable and require enumeration, Celsis® rapid detection is extremely useful to obtain the fastest time result (18-24 hours) when 0 CFU is typically expected, such as for water for injection (WFI) and bulk drug substance. To learn more about Celsis® rapid microbial detection from Charles River, visit criver.com/celsis

  • The Stem Cell Frontier: Translating Breakthrough Therapies

    7 janv. 2019

    A novel collaboration forged by the California Institute of Regeneration Medicine is helping stem cell scientists translate their therapies from the bench to the clinic.

  • AACR 2018 - Hot Topic in Oncology

    30 avr. 2018

    Our panel of experts discuss hot topics in oncology from AACR 2018.

  • Evie Meets the Team

    25 juil. 2018

    What would you say to the people who saved your life? Go behind the scenes with Evie and her family as they talk to the researchers who saved her life. #EveryPatient http://bit.ly/2EYTuXz

  • The Backbone of Patient Safety: Niva’s Journey

    17 juin 2019

    http://bit.ly/2V2NRfJ Every year, 38,000 Scoliosis patients undergo spinal fusion surgery. If left untreated, moderate to severe cases can lead to pain and increasing deformity, as well as potential heart and lung damage. Treating this condition relies on a number of medical devices, drugs, and therapies, which all need to be delivered timely, effectively, and most importantly, safely. Meet Niva, an 11-year old scoliosis patient who relies on sound quality control from the medical and pharmaceutical industries for her ongoing treatment. Watch the short video to uncover how her journey is impacted by your work.

  • IDD Team - Partnering with a CRO

    5 avr. 2018

    Discovery from Charles River is the partner of choice with a proven track record of successful drug development. Offering scientific excellence and integrated services that take clients from hit ID to IND, our client-focused collaborative team works with clients to find and follow the optimum path to market. Find out more: http://bit.ly/2JqkHRR

  • Focus on Parkinson’s Research

    4 déc. 2017

    Scientists from Charles River and Michael J. Fox Foundation discuss the preclinical picture.

  • Driving In Vitro Assays Towards the Clinic

    23 mai 2018

    Charles River is developing translational in vitro assay to steer your drug discovery through to clinic.

  • IDD Team – On Collaboration

    25 janv. 2018

    Are you faced with too many options on the drug discovery path? Knowing which step to take can be challenging. Collaborations with scientists at CR have a vested interest in the outcome of your project. Consulting with our scientists is two way street to solving problems and as such long term relationships are built and we share your passion for the work.

  • Partnering for Success

    20 déc. 2017

    It’s impossible to anticipate the challenges you’ll face on the journey to market. Your best asset is a nimble, versatile nonclinical partner who knows how to scale scientific hurdles, overcome regulatory snags, and clear a path to approval.

  • CRISPR and Tumor Progression

    18 avr. 2018

    Panel discussion from AACR 2018.

  • Overcoming pre-clinical challenges in novel cell therapy research and development

    23 juil. 2018

    Explore our cell and gene therapy R&D solutions: http://bit.ly/2mCPdxD

  • Charles River in Great Shape: Jim Foster on CNBC's Mad Money

    14 nov. 2019

    On November 11, 2019, Jim Foster, Chairman, President & CEO of Charles River joined Jim Cramer on Mad Money to discuss the biotech industry, growth in China, and the future of Charles River. According to Jim: “Our business is not linear. We talk about that all the time. People don’t start studies and stop studies congruent with our fiscal quarters, but we’re really thrilled with our long-term growth rates..." Additionally, we recently reported our third quarter results. In Q3 2019, revenue was 668.0 million, an increase of 14.1% from 585.3 million in Q3 2018. Learn more here: https://bit.ly/2JWc1o2

  • Field Trials Team Video

    30 nov. 2017

    Our fully-integrated, multidisciplinary Field Trials team have been clearing hurdles and paving the way to successful agrochemical registration for twenty years.

  • Delivering Therapies to the Clinic Faster

    8 juil. 2019

    Come together September 23-24, as we explore novel approaches to drug development that effectively reduce program timelines and accelerate delivery to the clinic. #CRLWorldCon Learn more: http://bit.ly/2KsIrIF

  • Charles River's Immuno-Oncology Translational Platform

    11 déc. 2018

    Charles River’s translational platform for immuno-oncology supports the collection of rich data to inform better decision making, moving you effectively from target discovery and validation through to humanized mouse models and on to the clinic. http://bit.ly/2yagL2w

  • Every Life - Mila's Story (Trailer)

    16 oct. 2019

    Drug development can take more than 10 years. Meet the Boston Children’s Hospital and Charles River team behind a tailormade therapy that was developed in a fraction of that time, for a single patient. Watch Mila’s story. #EveryLife . . . At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guides us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. To learn more, please visit: » Our website, criver.com » Eureka, our scientific blog, eureka.criver.com » Sounds of Science, our monthly podcast, eureka.criver.com/podcast » Vital Science, our monthly podcast, criver.com/vitalsciencepodcast » Bonus! You can subscribe to Sounds of Science and Vital Science on Apple Podcasts, Spotify or wherever else you get your podcasts. » Facebook, facebook.com/charlesriverlabs » LinkedIn, linkedin.com/company/charles-river-laboratories » Twitter, twitter.com/criverlabs » Instagram, @criverlabs

  • Biotech Symposium 2018

    11 juin 2018

    Join us September 10–12 for our 24th Annual Biotech Symposium, a three-day event that unites drug development professionals in an interactive setting to discuss the nonclinical development of biotherapeutics in La Jolla, CA. http://bit.ly/2In6pAi

  • Allyson's Journey

    28 août 2019

    In 2015 Dr. Berent became the Chief Science Officer for the Foundation for Angelman Syndrome Therapeutics and has been integral in driving the research portfolio in novel treatment options for this rare genetic disorder. In 2017 Dr. Berent became the Chielf Operating Officer of GeneTx Biotherapeutics, a company with a sole mission to advance antisense oligonucleotide therapies toward human clinical trials for the treatment of Angelman syndrome. Congratulations to her and the GenetX team on their partnership with Ultragenyx. Hear Allyson talk about the personal journey of drug development at #CRLWorldCon. Register today! http://bit.ly/2L6zaVZ

  • Translational Integrated Drug Discovery

    20 mars 2019

    Many biotech industry leaders are finding themselves in uncharted waters: the science is more sophisticated than ever, producing paradigm-altering treatments. But, historically high R&D costs and low success rates have emphasized the need to identify drugs focused on translationally-relevant targets in the most cost and time efficient way. How do you thrive in this new era, and where do CROs fit into the picture? John Montana, PhD, Corporate Vice President, Integrated Drug Development and Strategic Projects, Charles River explains how an integrated approach adds value to drug discovery programs. Learn more here: https://bit.ly/2EGYHAo

  • A Message from Jim Foster - Thank You for Being the Difference

    19 déc. 2019

    We should all be proud of our accomplishments this year, which can be reviewed in the video below. Thank you for everything you do, every day to help us fulfill our purpose: Together, we create healthier lives. I am grateful to be part of this impressive Charles River team. I look forward to building on our momentum in 2020. Interested in a career at Charles River? Apply online: https://jobs.criver.com/

  • IDD Team - Advice for Working with a CRO

    25 juil. 2018

    Don’t just throw it over the fence build relationships with scientists who have been on your side of the bench. Learn more: http://bit.ly/2L7Ir1w

  • Rare Disease Roundtable (#CRLworldcon 2018)

    12 oct. 2018

    How two parents put a face on Rare Disease. A discussion from our 2nd Annual World Congress.

  • Delivering the DNA (#CRLworldcon 2018)

    31 oct. 2018

    Challenges in using gene therapy to treat rare diseases. A discussion from our 2nd Annual World Congress.

  • Advancing and Excelling as a Mid-Sized Biotech

    2 mai 2018

    Finding the right combination of resources to meet the needs of a complex drug discovery project can be challenging, especially having your team smoothly interface with a variety of external partners. How do you keep up with all of the projects being run at various CROs?

  • Overcoming Obstacles as a Virtual Biotech

    2 mai 2018

    As a virtual biotech, you’re in a challenging situation. You need a streamlined process and a diverse group of experts to help your skeleton crew reach the exit point.

  • 2018 4th Annual QC Micro Workshop

    3 avr. 2018

    A recap of our successful 2017 event and what’s to come in 2018!

  • Simplicity from Complexity

    15 mars 2018

    Functional protein isolation by Capture Coumpound Mass Spectrometry (CCMS)

  • Society for Neuroscience 2018

    1 nov. 2018

    Dare to change the way you think about your program. We invite you to visit booth #2519 at Society for Neuroscience Annual Meeting to explore how Charles River can partner with you to solve current problems in your neuroscience drug discovery programs. For more information: http://bit.ly/2CSSsKA

  • IDD Team - Advice for Young Scientists

    21 juin 2018

    Learn more about our IDD Team: http://bit.ly/2A0zcXz

  • Biotech Symposium 2019

    2 août 2019

    Join us September 9-11 for our 25th Annual Biotech Symposium, a three-day event that unites drug development professionals in an interactive setting to discuss the nonclinical development of biotherapeutics in Carlsbad, CA. Register today! http://bit.ly/2ZaSIwL

  • South San Francisco, California Facility Video

    27 nov. 2018

    Our facility in South San Francisco offers sophisticated in vivo efficacy and pharmacokinetics testing to better understand neuroscience disease pathophysiology, and is a center of excellence for microdialysis and EEG testing.

  • Mila's Story - Collaboration and Hope

    19 déc. 2019

    Behind every patient stands thousands of scientists and researchers, all working together to develop life-saving drugs. As you may have seen, many employees were involved in developing personalized medicine for Mila, just over a year from her diagnosis. This amazing achievement, racing through the holidays to get Mila her drug, showcases the dedication of our employees. http://bit.ly/2BabGcv #EveryLife

  • IDD Team on NASH – One Disease, Many Approaches

    27 sept. 2018

    Joe Cornicelli, PhD, Sr Director, in vivo Pharmacology, describes the challenges and opportunities for researchers pursuing new treatments for non-alcoholic steatohepatitis (NASH)

Entreprises - Rhône (69) - L'Arbresle (69210)

Allez plus loin avec B-Reputation

Découvrez comment nos données peuvent répondre à vos besoins.

Veille stratégique

  • Fiches entreprises complètes
  • Alertes
  • Tableaux de bord
En savoir plus

Prospection

  • Fichiers de prospection sur mesure
  • 100 critères de segmentation
  • Adresses, mails et téléphones
En savoir plus

Enrichissement

  • Traitement de fichiers ou API
  • Siretisation et dédoublonnage
  • Information complète et indicateurs propriétaires
En savoir plus

Solution d'avis client

  • Collecte et vérification
  • Tableaux de bord d'analyse
  • Diffusion web et réseaux sociaux
En savoir plus